The recommendations address the following bacterial infections: acute bronchitis with chronic obstructive pulmonary disease exacerbations, community-acquired pneumonia, urinary tract infections and cellulitis.
Here is the guidance, as outlined in the report:
- For patients with COPD exacerbations and acute uncomplicated bronchitis who have clinical signs of a bacterial infection, antibiotic treatment duration should be limited to five days.
- For patients with community-acquired pneumonia, antibiotic treatment should last a minimum of five days. After that, extending the use of antibiotics should be guided by validated measures of clinical stability, such as a return of normal vital signs and the ability to eat.
- For women with uncomplicated bacterial cystitis, antibiotic duration should last five days if treating with nitrofurantoin, three days with trimethoprim-sulfamethoxazole, or a single dose when treating with fosfomycin.
- For men and women with uncomplicated pyelonephritis, clinicians should limit either fluoroquinolones to five to seven days, or trimethoprim-sulfamethoxazole for 14 days based on antibiotic susceptibility.
- For patients with nonpurulent cellulitis, prescribe a course of antibiotics active against streptococci for five to six days for those able to self-monitor and who can follow-up with primary care.
More articles on patient safety and outcomes:
Hospital at Home ‘cheat sheet’: 6 Qs on the care model, answered
Black patients have less access to ‘high quality’ hospitals, analysis finds
1 in 10 Black patients faces descrimination from healthcare staff
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
